Search

Advances in neuroscience are opening up the treatment options for central nervous system diseases - at the same time as the ageing population is increasing the market for these products.

Active Solar Buildings – entirely heated and cooled by solar thermal energy – should become the standard by 2030 if the vision of the EU’s latest Technology Platform is realised.

Drug companies finally have an incentive to carry out safety testing in children following new EU legislation approved last week.

The first protein drug extracted from the milk of a genetically modified animal has finally received European approval.

The TeGenero drug trial is complete, and an ongoing study is examing whether trial requirements should be changed. But, asks Nuala Moran, should the trial ever have been approved?

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.

Scientists from the University of Birmingham, UK, have powered a fuel cell from confectionary waste. They now want to form a consortium with investors and SMEs to apply for an EU Framework grant.

The Finnish developers of a new and tiny silicon-based timer circuit are looking for partners with application-specific engineering and marketing expertise to take the product further.

An unusual programme by the software giant to spin out its technology has netted nine sales to small companies - with more on the way.

A laser physicist in Saudi Arabia has devised a workable optical diagnostic tool to detect early cancer - and is now looking for partners to commercialise the technology.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

A team of researchers at ORNL has come up with the concept of nanofermentation, and, it seems, plans to use this as a trademark.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Frost & Sullivan puts some flesh on the bones of the idea that nanotechnology can be a profitable tool in drug development.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.

The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.

Open source software has broken the stranglehold of proprietary software vendors. Could the Biological Open Source initiative do the same in biotech?